Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer

Patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR benefit from treatment with EGFR small-molecule tyrosine-kinase inhibitors. However, the development of acquired resistance to EGFR inhibitors is universal and limits treatment efficacy. Over half of patients rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Phu N, Klempner, Samuel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310702/
https://www.ncbi.nlm.nih.gov/pubmed/28210165
http://dx.doi.org/10.2147/LCTT.S94337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310702/
https://www.ncbi.nlm.nih.gov/pubmed/28210165
http://dx.doi.org/10.2147/LCTT.S94337

Ejemplares similares